{"id":145296,"date":"2026-03-06T16:24:22","date_gmt":"2026-03-06T21:24:22","guid":{"rendered":"https:\/\/medcitynews.com\/?p=145296"},"modified":"2026-03-11T10:26:52","modified_gmt":"2026-03-11T14:26:52","slug":"servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/","title":{"rendered":"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma"},"content":{"rendered":"

Servier is expanding its cancer drug prospects through the $2.5 billion acquisition<\/a> of Day One Biopharmaceuticals, a biotech with a commercialized therapy for a type of pediatric glioma and clinical-stage assets that fit the French company\u2019s business strategy of pipeline and revenue growth, particularly in oncology.<\/p>\n

Per acquisition terms announced Friday, Servier will pay $21.50 in cash for each share of Day One, which is a 68% premium to the stock\u2019s Thursday closing price. When Day One went public in 2021<\/a>, it priced its shares at $16 each.<\/p>\n

Suresnes, France-based Servier has set a goal of reaching \u20ac10 billion in annual revenue by 2030, a target that includes \u20ac4 billion from oncology drugs. David Lee, CEO of U.S. subsidiary Servier Pharmaceuticals, said in an interview last year that much of that goal can be achieved with life cycle management, finding new indications for the drugs the company already has. Ongoing clinical trials are testing drug combinations that could bring existing Servier drugs to more types of cancer. But Lee said growth will also come from business deals.<\/p>\n

\u201cWe do want to make acquisitions ideally synergistic to our current portfolio, but we’re very open to areas that are really novel, innovative,\u201d he said.<\/p>\n

Day One\u2019s main asset is Ojemda, a small molecule approved as a treatment for pediatric low-grade glioma<\/a>, a type of brain cancer affecting children. This drug complements a Servier portfolio that includes Voranigo, which has FDA approval for treating two rare types of brain cancer<\/a>.<\/p>\n

Ojemda\u2019s 2024 accelerated FDA approval covered its use as a second-line treatment. A Phase 3 study is ongoing that could support expanding the drug to first-line use. Day One, named for the \u201cday one talk\u201d physicians have with patients and families about a cancer diagnosis and treatment plan, reported $155.4 million in Ojemda sales<\/a> in 2025, the product\u2019s first full year on the market. Paris-based Ipsen licensed rights to Ojemda outside of the U.S.; a European regulatory decision for the drug is expected this year.<\/p>\n

Antibody drug conjugates (ADCs) make up Day One\u2019s pipeline. Months after Ojemda\u2019s approval, Day One licensed a drug now called DAY301, an ADC that targets the protein PTK7<\/a> on cancer cells. Day One holds global rights to this drug, excluding Greater China, where Shanghai-based MabCare Therapeutics retains rights. DAY301 is currently in Phase 1 testing in solid tumors in adults and pediatric patients.<\/p>\n

Day One expanded its ADC prospects last year, agreeing to buy Mersana Therapeutics<\/a> in a deal that could reach up to $285 million in value if milestones are met. Mersana\u2019s main asset was emilatug ledadotin (emi-le), an ADC that targets B7-H4. Other companies developing ADCs for this target include GSK, which acquired its contender in a business deal<\/a>. Pfizer was pursuing B7-H4 but has since discontinued programs<\/a> for the target.<\/p>\n

In an email<\/a> sent to Day One employees Friday morning, CEO Jeremy Bender said Servier will enable Ojemda to reach many more patients as part of the French company\u2019s growing global footprint.<\/p>\n

\u201cServier has made incredible strides in cancer innovation and shares our aspirations to address real unmet needs by integrating the patient voice at every stage of the medicine life cycle,\u201d Bender wrote. \u201cServier\u2019s team is truly excited about the planned acquisition and looks forward to incorporating Ojemda and our growing pipeline into its growth plans.\u201d<\/p>\n

Servier is privately held and governed by a nonprofit foundation. The company\u2019s three core therapeutic areas are oncology, neurology, and cardiometabolism and venous diseases. Servier made a big splash in oncology by acquiring Shire\u2019s cancer business for $2.4 billion<\/a> in 2018. Three years later, Servier acquired the clinical-stage oncology assets of Agios Pharmaceuticals for $1.8 billion<\/a> up front. The targeted therapies from Agios have since won FDA approval, Tibsovo for a rare type of blood cancer<\/a> and Voranigo for astrocytoma and oligodendroglioma.<\/p>\n

Servier reported \u20ac6.9 billion (about $8 billion) in total revenue<\/a> for the 2024\/2025 fiscal year. Oncology is its fastest growing therapeutic area. About \u20ac2.2 billion ($2.5 billion) in revenue for the year came from oncology products, a 54.6% increase compared to the prior fiscal year. While Servier\u2019s annual report<\/a> does not break down revenue by product, it attributes much of the oncology revenue growth to Voranigo. Lee said this drug is projected to become a blockbuster seller. The report also lists 22 clinical-stage programs and 12 research projects in oncology, which is more than Servier\u2019s other therapeutic areas combined.<\/p>\n

The Servier annual report states a goal of securing one new marketing authorization per year in oncology. Business deals could help the company achieve that. Nearly a year ago, Servier reached a deal to develop a Black Diamond Therapeutics small molecule designed to target RAS and RAF alterations<\/a> in solid tumors. Last May, Servier acquired global rights to a BioNova Pharmaceuticals menin inhibitor<\/a> in development for leukemias. Last September, Servier paid Ideaya Biosciences $230 million up front for rights outside of the U.S. to darovasertib<\/a>, which is in late-stage development for a rare type of eye cancer.<\/p>\n

Servier\u2019s latest acquisition requires a majority of Day One stockholders to tender their shares. The deal must also pass regulatory muster. The companies expect to complete the transaction in the second quarter of this year.<\/p>\n

Image:\u00a0CGToolbox, Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Day One Biopharmaceuticals is Servier\u2019s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire\u2019s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children. <\/p>\n","protected":false},"author":25932,"featured_media":22341,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,54],"tags":[11982,14217,12102,46298,46027,39249,41348],"class_list":["post-145296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-pharma-channel","tag-brain-cancer","tag-cancer","tag-clinical-trials","tag-day-one-biopharmaceuticals","tag-deals","tag-mergers-and-acquisitions","tag-servier"],"acf":[],"yoast_head":"\nServier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Day One Biopharmaceuticals is Servier\u2019s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire\u2019s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-06T21:24:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T14:26:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"483\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma\",\"datePublished\":\"2026-03-06T21:24:22+00:00\",\"dateModified\":\"2026-03-11T14:26:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/\"},\"wordCount\":877,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg\",\"keywords\":[\"brain cancer\",\"cancer\",\"Clinical Trials\",\"Day One Biopharmaceuticals\",\"Deals\",\"Mergers and Acquisitions\",\"Servier\"],\"articleSection\":[\"BioPharma\",\"Pharma\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/\",\"name\":\"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg\",\"datePublished\":\"2026-03-06T21:24:22+00:00\",\"dateModified\":\"2026-03-11T14:26:52+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg\",\"width\":724,\"height\":483},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/","og_locale":"en_US","og_type":"article","og_title":"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma - MedCity News","og_description":"Day One Biopharmaceuticals is Servier\u2019s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire\u2019s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.","og_url":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/","og_site_name":"MedCity News","article_published_time":"2026-03-06T21:24:22+00:00","article_modified_time":"2026-03-11T14:26:52+00:00","og_image":[{"width":724,"height":483,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma","datePublished":"2026-03-06T21:24:22+00:00","dateModified":"2026-03-11T14:26:52+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/"},"wordCount":877,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg","keywords":["brain cancer","cancer","Clinical Trials","Day One Biopharmaceuticals","Deals","Mergers and Acquisitions","Servier"],"articleSection":["BioPharma","Pharma"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/","url":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/","name":"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg","datePublished":"2026-03-06T21:24:22+00:00","dateModified":"2026-03-11T14:26:52+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2018\/05\/GettyImages-635475308.jpg","width":724,"height":483},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/03\/servier-day-one-biopharmaceuticals-acquisition-glioma-cancer-oncology-ojemda-dawn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/145296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=145296"}],"version-history":[{"count":7,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/145296\/revisions"}],"predecessor-version":[{"id":145420,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/145296\/revisions\/145420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/22341"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=145296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=145296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=145296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}